3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
3
Hodgkin Disease
3
Sarcoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Peripheral Blood Stem Cell Transplantation
32
fludarabine phosphate
29
Cyclophosphamide
26
Whole-Body Irradiation
21
Cyclosporine
20
Busulfan
20
Mycophenolic Acid
19
Tacrolimus
16
Antilymphocyte Serum
14
Methotrexate
13
romidepsin
12
Etoposide
12
Filgrastim
11
Melphalan
9
Psychiatric Rehabilitation
8
Methylprednisolone
8
Dexamethasone
8
Bexarotene
8
Vorinostat
7
Flow Cytometry
7
Therapeutics
6
Radiotherapy
6
Calcium Dobesilate
6
Brentuximab Vedotin
6
Bortezomib
6
Alemtuzumab
6
sargramostim
5
fludarabine
5
denileukin diftitox
5
Polymerase Chain Reaction
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Cutaneous
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts